All Stories

  1. Improving the prognosis for lung cancer patients

    Article • Acta Oncologica, July 2019, Taylor & Francis

    Dr Seppo W. Langer

  2. Dexrazoxane for the treatment of chemotherapy-related side effects

    Article • Cancer Management and Research, September 2014, Taylor & Francis

    Dr Seppo W. Langer

  3. Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms

    Article • Acta Oncologica, August 2014, Taylor & Francis

    Dr Seppo W. Langer, Clinical Chair Professor Henning Gronbaek

  4. Perioperative rehabilitation in operation for lung cancer (PROLUCA) – rationale and design

    Article • BMC Cancer, June 2014, Springer Science + Business Media

    Dr Seppo W. Langer, Professor Timothy Charles Skinner

  5. PET/CT in therapy evaluation of patients with lung cancer

    Article • Expert Review of Anticancer Therapy, April 2014, Taylor & Francis

    Dr Seppo W. Langer, Professor Andreas Kjaer

  6. Topotecan Monotherapy in Heavily Pretreated Patients with Progressive Advanced Stage Neuroendocrine Carcinomas

    Article • Journal of Cancer, January 2014, Ivyspring International Publisher

    Dr Seppo W. Langer, Professor Andreas Kjaer

  7. Extravasation Reactions

    Article • November 2013, Wiley

    Dr Seppo W. Langer

  8. “EXHALE”: exercise as a strategy for rehabilitation in advanced stage lung cancer patients: a randomized clinical trial comparing the effects of 12 weeks supervised exercise intervention versus usual care for advanced stage lung cancer patients

    Article • BMC Cancer, October 2013, Springer Science + Business Media

    Dr Seppo W. Langer

  9. A placebo-controlled, randomized phase II study of maintenance enzastaurin following whole brain radiation therapy in the treatment of brain metastases from lung cancer

    Article • Lung Cancer, October 2012, Elsevier

    Dr Seppo W. Langer

  10. Safety and feasibility of a combined exercise intervention for inoperable lung cancer patients undergoing chemotherapy: A pilot study

    Article • Lung Cancer, February 2012, Elsevier

    Dr Seppo W. Langer

  11. Temozolomide as Second or Third Line Treatment of Patients with Neuroendocrine Carcinomas

    Article • The Scientific World JOURNAL, January 2012, Hindawi Publishing Corporation

    Dr Seppo W. Langer, Professor Andreas Kjaer

  12. Treatment of anthracycline extravasation from centrally inserted venous catheters

    Article • Oncology Reviews, December 2011, PAGEPress Publications

    Dr Seppo W. Langer

  13. Treatment of experimental extravasation of amrubicin, liposomal doxorubicin, and mitoxantrone with dexrazoxane

    Article • Cancer Chemotherapy and Pharmacology, December 2011, Springer Science + Business Media

    Dr Seppo W. Langer

  14. First-line treatment of patients with disseminated poorly differentiated neuroendocrine carcinomas with carboplatin, etoposide, and vincristine: A single institution experience

    Article • Acta Oncologica, May 2011, Taylor & Francis

    Dr Seppo W. Langer, Professor Andreas Kjaer

  15. RE: Kesik et al: Melatonin Ameliorates Doxorubicin-induced Skin Necrosis in Rats

    Article • Annals of Plastic Surgery, November 2010, Wolters Kluwer Health

    Dr Seppo W. Langer

  16. Extravasation of Chemotherapy

    Article • Current Oncology Reports, May 2010, Springer Science + Business Media

    Dr Seppo W. Langer

  17. A murine experimental anthracycline extravasation model: Pathology and study of the involvement of topoisomerase II alpha and iron in the mechanism of tissue damage

    Article • Toxicology, February 2010, Elsevier

    Dr Seppo W. Langer

  18. A Recall Reaction and Call for Action

    Article • Onkologie, January 2010, Karger Publishers

    Dr Seppo W. Langer

  19. Treatment of small cell lung cancer

    Article • December 2008, Taylor & Francis

    Dr Seppo W. Langer

  20. Phase II Study of a 3-Day Schedule with Topotecan and Cisplatin in Patients with Previously Untreated Small Cell Lung Cancer and Extensive Disease

    Article • Journal of Thoracic Oncology, August 2008, Elsevier

    Dr Seppo W. Langer

  21. Treatment of anthracycline extravasation from centrally inserted venous catheters

    Article • Oncology Reviews, July 2008, Springer Science + Business Media

    Dr Seppo W. Langer

  22. Metastasizing malignant pleomorphic adenoma in a young man

    Article • Apmis, July 2007, Wiley

    Dr Seppo W. Langer

  23. Other uses of dexrazoxane: savene, the first proven antidote against anthracycline extravasation injuries

    Article • Cardiovascular Toxicology, April 2007, Springer Science + Business Media

    Dr Seppo W. Langer

  24. PET/CT imaging in response evaluation of patients with small cell lung cancer

    Article • Lung Cancer, October 2006, Elsevier

    Dr Seppo W. Langer

  25. Treatment of anthracycline extravasation in mice with dexrazoxane with or without DMSO and hydrocortisone

    Article • Cancer Chemotherapy and Pharmacology, July 2005, Springer Science + Business Media

    Dr Seppo W. Langer

  26. Pharmacokinetics of etoposide in cancer patients treated with high-dose etoposide and with dexrazoxane (ICRF-187) as a rescue agent

    Article • Cancer Chemotherapy and Pharmacology, January 2004, Springer Science + Business Media

    Dr Seppo W. Langer

  27. Pharmacokinetics of etoposide in cancer patients treated with high-dose etoposide and with dexrazoxane (ICRF-187) as a rescue agent

    Article • Cancer Chemotherapy and Pharmacology, October 2003, Springer Science + Business Media

    Dr Seppo W. Langer

  28. Metabolism of dexrazoxane (ICRF-187) used as a rescue agent in cancer patients treated with high-dose etoposide

    Article • Cancer Chemotherapy and Pharmacology, August 2003, Springer Science + Business Media

    Dr Seppo W. Langer

  29. P-61 Polychemotherapy including topotecan combined with twice-daily accelerated radiotherapy in small cell lung cancer (SCLC). Preliminary data from a phase II trial

    Article • Lung Cancer, August 2003, Elsevier

    Dr Seppo W. Langer

  30. A phase II study of a 3-day schedule with topotecan and cisplatin every three weeks in patients with previously intreated small cell lung cancer and extensive disease

    Article • Lung Cancer, August 2003, Elsevier

    Dr Seppo W. Langer

  31. DEXRAZOXANE - A PROMISING ANTIDOTE IN THE TREATMENT OF ACCIDENTAL EXTRAVASATION OF ANTHRACYCLINES

    Article • Scandinavian Journal of Plastic and Reconstructive Surgery and Hand Surgery, January 2003, Taylor & Francis

    Dr Seppo W. Langer

  32. Brain relapses in chemotherapy-treated small cell lung cancer: a retrospective review of two time-dose regimens of therapeutic brain irradiation

    Article • Lung Cancer, September 1996, Elsevier

    Dr Seppo W. Langer

  33. Asbestos‐induced lung injury among danish jewelry workers

    Article • American Journal of Industrial Medicine, December 1994, Wiley

    Dr Seppo W. Langer